Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosutinib and Pemetrexed in metastatic solid tumors
NCT03023319Phase 1Completed
- Start
- Dec 2019
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of bosutinib in non-small cell lung cancer (NSCLC), mesothelioma, bladder cancer and 6 more. Primary endpoint: Dose-limiting toxicity at 21 days. Started Dec 2019; status: completed.
02
Drugs
bosutinib
03
Conditions
non-small cell lung cancer (NSCLC)mesotheliomabladder cancerurethral cancerovarian cancer
Beyond the preview
Go deeper on NCT03023319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03023319.